A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2007-05-10
Target enrollment:
Participant gender:
Summary
The compound GW642444 has previously been found to be well tolerated with no significant side
effects in subjects with asthma and healthy volunteers. This study will assess the safety and
tolerability of GW642444 in subjects with COPD in order to obtain information to support
dosing in a broader population of subjects with COPD